```html

Jungling’s Disease (Chronic Inflammatory Demyelinating Polyneuropathy)

Overview

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), sometimes called “Jungling’s disease” in older literature, is an acquired immune‑mediated disorder that causes progressive weakness and impaired sensation in the peripheral nerves. The condition results from inflammation that damages the myelin sheath—the protective covering of nerves—leading to slowed or blocked nerve signal transmission.

Who it affects: CIDP can occur at any age but shows two peaks: a younger adult group (20‑40 years) and an older group (>60 years). Both men and women are affected, with a slight male predominance (≈55 % male).<sup>[1] Mayo Clinic</sup>

Prevalence: The disease is rare, affecting about 1–2 per 100,000 people worldwide.<sup>[2] NIH</sup> In the United States, roughly 8–10 % of all patients referred for peripheral neuropathy meet the diagnostic criteria for CIDP.

Symptoms

Symptoms develop gradually (over weeks to months) and may fluctuate. The classic pattern is symmetric involvement of the limbs, but variants exist.

• Muscle weakness – typically begins in the legs and may progress to the arms; difficulty climbing stairs, rising from a chair, or lifting objects.
• Reduced or absent reflexes – deep tendon reflexes (e.g., knee‑jerk) are often diminished or lost.
• Sensory changes – numbness, tingling (paresthesia), or burning sensations, especially in the feet and hands.
• Loss of proprioception – trouble sensing limb position, leading to clumsiness or a “foot‑slap” gait.
• Impaired coordination – difficulty with fine motor tasks such as buttoning a shirt.
• Fatigue – generalized tiredness that worsens after activity.
• Pain – neuropathic pain in the affected limbs; often described as aching or electric‑shock‑like.
• Autonomic dysfunction (rare) – sweating abnormalities, orthostatic hypotension, or bladder issues.
• Facial or bulbar weakness (variant) – difficulty speaking, chewing, or swallowing.

Symptoms are usually symmetrical and proximal (closer to the trunk) first, distinguishing CIDP from many other neuropathies.

Causes and Risk Factors

Exact cause remains unclear, but CIDP is widely accepted as an autoimmune condition. The immune system mistakenly attacks myelin proteins, leading to demyelination and, in some cases, secondary axonal loss.

Identified Triggers

• Infections – antecedent viral (e.g., HIV, hepatitis C) or bacterial infections have been documented in up to 25 % of cases.<sup>[3] CDC</sup>
• Vaccinations – rare reports link CIDP onset to certain vaccines (e.g., influenza), but causality is not established.
• Systemic autoimmune diseases – lupus, rheumatoid arthritis, and Sjögren’s syndrome increase risk.
• Hematologic disorders – paraproteinemias (e.g., MGUS, Waldenström macroglobulinemia) are associated with “IgM‑associated CIDP.”
• Diabetes mellitus – can coexist and exacerbate nerve damage.

Risk Factors

• Age > 50 years (higher incidence in seniors)
• Male sex (slight predominance)
• Family history of other autoimmune disorders
• Recent infection or immunization (within 3‑6 months)
• Presence of a monoclonal gammopathy

Diagnosis

Because CIDK mimics many other neuropathies, a thorough evaluation is essential.

Clinical Criteria

The European Federation of Neurological Societies (EFNS) and the American Academy of Neurology (AAN) recommend that a diagnosis be based on:

1. Progressive or relapsing‑remitting motor and sensory deficit lasting ≥ 8 weeks.
2. Electrodiagnostic evidence of demyelination in ≥ 2 nerves.
3. Supportive evidence (e.g., CSF protein elevation, MRI nerve‑root enhancement, or nerve biopsy showing demyelination).

Key Diagnostic Tests

• Electromyography (EMG) & Nerve Conduction Studies (NCS) – show slowed conduction velocities, prolonged distal latencies, and temporal dispersion, hallmark signs of demyelination.
• Lumbar Puncture – cerebrospinal fluid (CSF) typically shows albuminocytologic dissociation: elevated protein (> 55 mg/dL) with normal white‑cell count.
• MRI of the spine – “root enhancement” (gadolinium uptake of the cauda equina or spinal nerve roots) supports inflammation.
• Nerve or muscle biopsy – reserved for atypical cases; reveals loss of myelin and macrophage infiltration.
• Blood tests – screen for diabetes, thyroid disease, vitamin deficiencies, HIV, hepatitis, ANA, and serum protein electrophoresis.

Early referral to a neurologist experienced in peripheral nerve disorders dramatically improves outcomes.

Treatment Options

Therapy aims to stop immune attack, restore nerve function, and prevent disability. Treatment is individualized based on disease severity, comorbidities, and response to prior therapy.

First‑Line Immunotherapies

• Corticosteroids (e.g., prednisone 1 mg/kg/day) – effective in ~70 % of patients. Tapered over months to reduce side‑effects.
• Intravenous Immunoglobulin (IVIG) – 2 g/kg divided over 2–5 days, repeated every 3–6 weeks as needed. Rapidly improves strength in many patients.
• Plasma Exchange (PLEX) – 4–6 exchanges over 1–2 weeks; useful when steroids/IVIG are contraindicated or ineffective.

Approximately 30‑40 % of patients need a combination of the above or a switch to a different modality.

Second‑Line / Maintenance Therapies

• Immunosuppressants – azathioprine, mycophenolate mofetil, methotrexate, or cyclophosphamide for steroid‑sparing.
• Rituximab – anti‑CD20 monoclonal antibody; shows benefit in IgM‑associated CIDP and refractory cases.<sup>[4] Cleveland Clinic</sup>
• Subcutaneous Immunoglobulin (SCIG) – home‑based alternative to IVIG for stable patients.

Symptomatic & Supportive Care

• Physical therapy – strength training, gait training, and balance exercises.
• Occupational therapy – adaptive equipment for ADLs (activities of daily living).
• Pain management – gabapentinoids, tricyclic antidepressants, or duloxetine.
• Assistive devices – canes, walkers, or ankle‑foot orthoses as needed.

Lifestyle Adjustments

Maintaining optimal glucose control, regular moderate exercise, adequate sleep, and a balanced diet help preserve nerve health and reduce medication side‑effects.

Living with Jungling’s Disease (CIDP)

Successful long‑term management combines medical treatment with practical daily strategies.

Daily Management Tips

• Medication adherence – set alarms or use pill organizers; never stop steroids abruptly.
• Exercise routine – low‑impact activities (walking, stationary cycling, swimming) 3‑5 times per week; consult a physiotherapist familiar with CIDP.
• Foot care – inspect feet daily for sores; wear well‑fitted, supportive shoes; consider custom orthotics.
• Energy conservation – break tasks into smaller steps, sit while cooking or dressing, use adaptive kitchen tools.
• Nutrition – protein‑rich foods support muscle repair; ensure adequate B‑vitamins and omega‑3 fatty acids.
• Stress management – mindfulness, yoga, or counseling can reduce disease‑flaring stress hormones.
• Regular follow‑up – schedule neurology visits every 3–6 months, or sooner if symptoms change.
• Vaccination awareness – keep flu and pneumococcal vaccines up‑to‑date; discuss timing with your neurologist.

Prevention

Because CIDP is largely immune‑mediated, primary prevention is limited. However, risk reduction strategies include:

• Prompt treatment of infections (especially HIV, hepatitis C, and severe bacterial infections).
• Management of chronic diseases that can trigger or worsen neuropathy (e.g., diabetes, thyroid disorders).
• Avoidance of unnecessary immunizations or medications only when a clear benefit outweighs risk; discuss concerns with a physician.
• Screening for monoclonal gammopathies in patients with unexplained neuropathy, enabling earlier targeted therapy.

Complications

If left untreated or poorly controlled, CIDP can lead to:

• Permanent disability – severe, irreversible weakness or contractures.
• Respiratory muscle involvement – rare but may require ventilatory support.
• Chronic pain syndromes – neuropathic pain that impairs sleep and mood.
• Deep vein thrombosis (DVT) – due to prolonged immobility.
• Side‑effects from long‑term steroids – osteoporosis, diabetes, hypertension, cataracts.
• Psychosocial impact – depression, anxiety, reduced quality of life.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Chronic inflammatory demyelinating polyneuropathy (CIDP).” Updated 2023. https://www.mayoclinic.org
2. National Institute of Neurological Disorders and Stroke. “CIDP Fact Sheet.” 2022. https://www.ninds.nih.gov
3. Centers for Disease Control and Prevention. “Peripheral Neuropathy and Infections.” 2021. https://www.cdc.gov
4. Cleveland Clinic. “Rituximab for Refractory CIDP.” 2023. https://my.clevelandclinic.org
5. World Health Organization. “Guidelines for the Management of Peripheral Neuropathies.” 2020.

```